Twin Health has raised another $53 million to fund its ‘digital twin’ platform, which provides a model of a patient’s unique metabolism and can help people manage diabetes and weight loss.
The investment, led by Denmark’s Maj Invest, will be used to build Twin Health’s presence in health plans and among corporate clients, which use its AI-powered platform to improve the health of their members and employees.
Meanwhile, Twin Health has also announced the results of a clinical trial in the New England Journal of Medicine Catalyst, conducted by researchers at the Cleveland Clinic in the US, which showed that its digital twin can be an effective treatment for diabetes and weight loss, without the use of high-cost medications.
In the 150-subject study – which focused on people with type 2 diabetes being managed in primary care – 71% of participants using the Twin system and standard drug metformin met the primary endpoint of achieving a haemoglobin A1C level below 6.5%, compared to 2.4% of a control group who received standard care alone.
At the same time, those using the AI-powered tool were able to reduce the use of blood sugar-lowering medications, including GLP-1 agonists, SGLT2 inhibitors, DPP4 inhibitors, and insulin, compared to the control arm.
For example, 85% of participants in the Twin Health program eliminated GLP-1s, which the company said showed that many people living with type 2 diabetes can sustain clinical goals without long-term dependence on these drugs. Moreover, the software users lost more weight – 8.6% of their baseline level versus 4.6% with standard care.
In a statement, the company said its Twin platform is helping employers and health plans “meet growing demand for responsible GLP-1 strategies” and reduce costs in the face of massive demand for these weight-loss therapies.
It draws on data collected daily from wearable sensors, clinical lab testing, and patient self-reporting, and provides guidance from healthcare support staff that is tailored to an individual’s metabolism and habits in nutrition, sleep, and physical activity.
“We address the root causes of chronic metabolic diseases to improve and reverse diabetes,” said Jahangir Mohammed, Twin Health’s founder and chief executive.
“Members use their own biomarker data – not population averages – to create their own AI digital twin that guides them in a way that is engaging, precise, and sustainable,” he added. “We believe metabolic health is a continuous condition, not an episodic event, and Twin delivers continuous, 24/7 guidance to meet that reality.”
The new cash injection comes less than two years after Twin Health raised $50 million in a private round, and four years after a $140 million Series C.
